Glenmark Pharmaceuticals Settles Antitrust Lawsuit with Humana for $15.28 Million

Glenmark Pharmaceuticals Ltd. has entered into a settlement agreement with Humana, Inc. to resolve consolidated antitrust and consumer protection lawsuits in the U.S., bringing closure to a long-standing legal overhang. Key Highlights: Settlement Amount: Glenmark USA will pay a total of $15.28 million (inclusive of interest) in two installments. Nature of Claims: The lawsuits alleged price-fixing and anti-competitive conduct related to generic pharmaceutical products. Company Stance: Glenmark USA explicitly denies all allegations and maintains that the settlement does not constitute an admission of liability, wrongdoing, or illegality. Financial Impact: The entire settlement amount has already been fully provisioned in the company’s financial statements. Consequently, this resolution will have no material adverse impact on Glenmark’s current financial position or cash flows. Strategic Context: This settlement is part of a broader wave of industry-wide litigation dating back to 2016, involving numerous generic drug manufacturers. By resolving these specific complaints filed by Humana, Glenmark successfully mitigates a legacy legal risk, allowing management to maintain focus on its core business operations and growth initiatives without the distraction of prolonged litigation. $GLENMARK